{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:DOC-4S65DCZB/08e296a1-12cb-40dd-b5c6-31364d833473/PDF","dcterms:extent":"1521 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:DOC-4S65DCZB/8a7a0590-0f55-4cc0-b032-db79135f6183/TEXT","dcterms:extent":"74 KB"}],"edm:TimeSpan":{"@rdf:about":"1929-2026","edm:begin":{"@xml:lang":"en","#text":"1929"},"edm:end":{"@xml:lang":"en","#text":"2026"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:DOC-4S65DCZB","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/urn:nbn:si:spr-a30mfzkp"},{"@xml:lang":"sl","#text":"Zdravniški vestnik"}],"dcterms:issued":"2023","dc:creator":["Ferk, Polonca","Kuret, Tadeja"],"dc:contributor":"Ferk, Polonca","dc:format":[{"@xml:lang":"sl","#text":"številka:11/12"},{"@xml:lang":"sl","#text":"letnik:92"},{"@xml:lang":"sl","#text":"str. 481-495"}],"dc:identifier":["DOI:10.6016/ZdravVestn.3411","ISSN:1318-0347","COBISSID:179355651","URN:URN:NBN:SI:doc-4S65DCZB"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Slovensko zdravniško društvo"},"dc:subject":[{"@xml:lang":"sl","#text":"melanom"},{"@xml:lang":"en","#text":"melanoma"},{"@xml:lang":"sl","#text":"odpornost na zdravljenje"},{"@xml:lang":"sl","#text":"osebna medicina"},{"@xml:lang":"en","#text":"personal medicine"},{"@xml:lang":"sl","#text":"posameznocelične analize"},{"@xml:lang":"en","#text":"RNA sequencing"},{"@xml:lang":"sl","#text":"sekvenciranje RNK"},{"@xml:lang":"en","#text":"single cell analyses"},{"@xml:lang":"en","#text":"therapy resistance"}],"dcterms:temporal":{"@rdf:resource":"1929-2026"},"dc:title":{"@xml:lang":"sl","#text":"Sekvenciranje RNK na ravni posameznih celic| revolucionarna tehnologija, ki nadgrajuje razumevanje kompleksnih bolezni in spodbuja oseben pristop k zdravljenju - primer melanoma kože| Single-cell RNA sequencing| a revolutionary technology that has enhanced our understanding of complex human diseases and paved the way towards precision medicine - melanoma example|"},"dc:description":[{"@xml:lang":"sl","#text":"Single-cell RNA sequencing (scRNAseq) allows us to simultaneously determine the transcriptome (the set of all RNA mole-cules) in each individual cell in the sample or tissue of interest with high resolution and accuracy. It represents an import-ant tool, especially for studying complex biological systems and tissues, such as tumour tissues, where cellular complex-ity and diversity are extremely important. In this article, we focused on cutaneous melanoma, one of the most common and aggressive cancers in industrialized countries. Although, with the introduction of immunotherapy, the prognosis of melanoma has improved significantly, there are still approximately 30-40% of patients in whom this type of therapy is unsuccessful. Recent data obtained using scRNAseq have shown that the mechanism of resistance to treatment with im-mune checkpoint inhibitors is very complex. Various factors that vary from patient to patient can affect therapy resistance, including the presence and phenotype of exhausted CD8+ T lymphocytes, BRAF gene mutation, melanocyte phenotype, the presence and phenotype of cells of myeloid origin, and the interaction between all cells that make up the tumour microenvironment. In the future, an individualized treatment approach based on the molecular and cellular definition of the tumour and its microenvironment, as well as predictive biomarkers, will become increasingly important by greatly improving the efficacy of treatment. We can also expect a new wave of development of more effective therapies for the treatment of melanoma, mostly due to significant advances in technologies, such as scRNAseq, which allows us to precise-ly determine the genomic and transcriptomic characteristics of thousands of individual cells in the tumour microenviron-ment simultaneously, thus identifying new potential therapeutic targets. However, due to certain limitations, scRNAseq technology is currently used only for research purposes and has yet to be introduced into real clinical practice"},{"@xml:lang":"sl","#text":"Tehnologija sekvenciranja RNK na ravni posameznih celic (scRNAseq) nam omogoča, da z visoko ločljivostjo in na-tančnostjo naenkrat določimo nabor vseh molekul RNK v vsaki posamezni celici, ki se nahaja v določenem vzorcu oz. tkivu. Danes je scRNAseq pomembno orodje predvsem za proučevanje kompleksnih bioloških sistemov in tkiv, kot je tumorsko tkivo, kjer je velika celična raznolikost ključnega pomena. V članku navajamo primer melanoma kože, ki je eden najpogo-stejših in najbolj agresivnih rakov v razvitem svetu. Čeprav se je v zadnjem času z uvedbo imunske terapije napoved izida melanoma bistveno izboljšala, pa je še vedno približno 30–40 % bolnikov, pri katerih tovrstno zdravljenje ni uspešno. Novi podatki, pridobljeni z uporabo scRNAseq, so razkrili, da je mehanizem odpornosti na zdravljenje z zaviralci imunskih nad-zornih točk zelo kompleksen, da na to poleg prisotnosti in fenotipa izčrpanih limfocitov T CD8+ vpliva tudi mutacija v genu BRAF, fenotip melanocitov, prisotnost in fenotip celic mieloičnega izvora, prisotnost fibroblastov različnega fenotipa ter interakcije med vsemi celicami, ki tvorijo tumorsko mikrookolje. V prihodnosti bo torej vse bolj pomemben oseben pristop zdravljenja, ki bo temeljil na molekularni in celični opredelitvi tumorja in njegovega mikrookolja ter na napovednih biolo-ških označevalcih. Z uporabo tehnologije scRNAseq se bomo lahko cilju osebne medicine zelo približali, saj nam omogoča identifikacijo posameznih celic in celičnih označevalcev, ki bi lahko napovedali odziv bolnika na zdravljenje in omogoča bolj ciljano odločitev za vrsto zdravljenja za posameznega bolnika. Na ta način bi se izognili principu zdravljenja, ki temelji na “poskusu in napaki” ter tako bistveno izboljšali učinkovitost zdravljenja. Zaenkrat pa se tehnologija scRNAseq uporab-lja zgolj v raziskovalne namene, zato zaradi določenih omejitev ni uvedena v dejansko klinično prakso"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:DOC-4S65DCZB","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:DOC-4S65DCZB"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:DOC-4S65DCZB/08e296a1-12cb-40dd-b5c6-31364d833473/PDF"},"edm:rights":{"@rdf:resource":"http://creativecommons.org/licenses/by-nc/4.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Slovensko zdravniško društvo"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:DOC-4S65DCZB/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:DOC-4S65DCZB"}}}}